Therapeutic potential of valproic acid for retinitis pigmentosa

British Journal of Ophthalmology

Volumn 95, Issue 1, 2011, Pages 89-93

  Clemson, C M ^a   Tzekov, R ^a   Krebs, M ^b   Checchi, J M ^a   Bigelow, C ^c   Kaushal, Shalesh ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; RETROSPECTIVE STUDY; STOMACH IRRITATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RETINITIS PIGMENTOSA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VALPROIC ACID; VISUAL ACUITY; VISUAL FIELD TESTS; VITAMIN A; YOUNG ADULT;

EID: 78650806345     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.175356     Document Type: Article

References (25)

1. Delyfer MN, Leveillard T, Mohand-Said S, et al. Inherited retinal degenerations: therapeutic prospects. Biol Cell 2004;96:261-9. (Pubitemid 38618754)
2. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006;368:1795-809.
3. Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;111:761-72.
4. Berson EL, Rosner B, Sandberg MA, et al. Vitamin A supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;111:1456-9.
5. Li T, Sandberg MA, Pawlyk BS, et al. Effect of vitamin A supplementation on rhodopsin mutants threonine-17 → methionine and proline-347 → serine in transgenic mice and in cell cultures. Proc Natl Acad Sci U S A 1998;95:11933-8.
6. Noorwez SM, Ostrov DA, McDowell JH, et al. A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Invest Ophthalmol Vis Sci 2008;49:3224-30.
7. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78. (Pubitemid 34062289)
8. Dragunow M, Greenwood JM, Cameron RE, et al. Valproic acid induces caspase 3-mediated apoptosis in microglial cells. Neuroscience 2006;140:1149-56.
9. Chen PS, Wang CC, Bortner CD, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007;149:203-12.
10. Kim HJ, Rowe M, Ren M, et al. Histone deacetylase inhibitors exhibit antiinflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007;321:892-901.
11. Suuronen T, Nuutinen T, Ryhanen T, et al. Epigenetic regulation of clusterin/ apolipoprotein J expression in retinal pigment epithelial cells. Biochem Biophys Res Commun 2007;357:397-401.
12. Yasuda S, Liang MH, Marinova Z, et al. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 2009;14:51-9.
13. Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull. 2003;37(Suppl 2):5-16.
14. Dagnelie G. Conversion of planimetric visual-field data into solid angles and retinal areas. Clinical Vision Sciences 1990;5:95-100. (Pubitemid 20075829)
15. Massof R, Dagnelie G, Benzschawel T, et al. First order dynamics of visual field loss in retinitis pigmentosa. Clin Vision Sci 1990;5:1-26. (Pubitemid 20075821)
16. Merin S, Obolensky A, Farber MD, et al. A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies. J Ocul Pharmacol Ther 2008;24:80-6.
17. Berson EL, Rosner B, Weigel-DiFranco C, et al. Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. Invest Ophthalmol Vis Sci 2002;43:3027-36.
18. Piepers S, Veldink JH, de Jong SW, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol 2009;66:227-34.
19. Vingolo EM, Rocco M, Grenga P, et al. Slowing the degenerative process, long lasting effect of hyperbaric oxygen therapy in retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2008;246:93-8.
20. Chapman A, Keane PE, Meldrum BS, et al. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982;19:315-59.
21. Macdonald RL, Bergey GK. Valproic acid augments GABA-mediated postsynaptic inhibition in cultured mammalian neurons. Brain Res 1979;170:558-62.
22. Feng HL, Leng Y, Ma CH, et al. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008;155:567-72.
23. Leng Y, Liang MH, Ren M, et al. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008;28:2576-88. (Pubitemid 351348211)
24. Kanai H, Sawa A, Chen RW, et al. Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J 2004;4:336-44.
25. Kubota A, Nishida K, Nakashima K, et al. Conversion of mammalian Muller glial cells into a neuronal lineage by in vitro aggregate-culture. Biochem Biophys Res Commun 2006;351:514-20.